YMAB - Y-mAbs Therapeutics

-

$undefined

N/A

(N/A)

Y-mAbs Therapeutics NasdaqGS:YMAB Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Location: 202 Carnegie Center, Princeton, NJ, 08540, United States | Website: https://www.ymabs.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

155.4M

Cash

60.31M

Avg Qtr Burn

-4.787M

Short % of Float

11.24%

Insider Ownership

11.50%

Institutional Own.

70.98%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DANYELZA® (naxitamab-gqgk) Details
Spinal cord tumor, Neuroblastoma, Spinal cord injury, Cancer, Osteosarcoma

Approved

Quarterly sales

Phase 2

Update

Phase 2

Update

CD38-SADA Details
Cancer, Non-Hodgkin lymphoma

Phase 1

Data readout

GD2-SADA Details
Melanoma, Small cell lung cancer, Sarcoma, Neuroblastoma

Phase 1

Data readout

SADA Details
Cancer, Neuroblastoma

IND

Submission

GD2-GD3 Vaccine Details
Rare diseases, Spinal cord tumor, Neuroblastoma, Cancer

Failed

Discontinued

Failed

Discontinued